Peptide administration for lung fibrosis treatment using formulation based on medusa technology. develop a sustained release formulation os p144 or p17, loquid or freeze-dried form, for subcutaneous administration route and carry on preclinical and clinical trials.
To investigate the possibility of developing biomarkers for hcc prognosis and companion diagnostics by using advanced sequencing technologies (ngs) and the data analysis algorithms for a set of target biomarkers.
Development of a comprehensive in silico platform for the prediction and analysis of protein - noble gas interactions and potential therapeutic applications across the entire human proteome.
A eureka consortium of scientists from research institutions and 8 leading plant breeding/biotechnology companies will apply innovative molecular techniques to solve urgent quality problems in the most important european cereals.
Development of anti-cancer vaccines. The technology combines a promising tumour antigen with a powerful vaccine vector to provide a specific immunotherapy.
Acceleration and diversification of flavour formation in semi-hard cheeses, by controlling amino-acid catabolism with lactic acid bacteria (lab).
A novel platform for the sustained intracellular delivery of therapeutic molecules.
The objective is to design and develop a histamine h3 receptor inverse agonist as a novel type of drug for use in the treatment of alzheimer's disease, obesity and/or epilepsy.
Propionic acid bacteria (pab) are applied, together with other dairy bacteria, for development of a swiss flavour concentrate and for improvement of ripening of semi-hard cheeses. The focus is on (directing) routes of flavour formation by pab.
Development of a natural component based on clays, diatomite and seaweeds which will replace the current growth promoters and the fight against mycotoxicosis in animal feed.